Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: Before and after transplantation

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 8, 2011, Pages 641-652

  Idilman, Ramazan ^a   Arat, Mutlu ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

allogeneic hematopoietic stem cell transplantation; HBV reactivation; hepatitis B virus

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; PEGINTERFERON; STEROID; TELBIVUDINE; TENOFOVIR DISOPROXIL;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DONOR SELECTION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION SENSITIVITY; NONHUMAN; PREMEDICATION; REVIEW; SCREENING TEST; SERODIAGNOSIS; SURVIVAL RATE; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT PLANNING; VIRUS MUTATION; VIRUS REACTIVATION; VIRUS REPLICATION;

ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; RISK FACTORS; VIRUS ACTIVATION;

EID: 80051764096     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.79     Document Type: Review

References (142)

1. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 45, 507-539 (2007). (Pubitemid 46374607)
2. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N. Engl. J. Med. 350, 1118-1129 (2004). (Pubitemid 38298992)
3. Lee WM. Hepatitis B infection. N. Engl. J. Med. 337, 1733-1745 (1997).
4. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepatol. 11, 97-107 (2004). (Pubitemid 38365759)
5. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin. Liver Dis. 25(Suppl. 1), 3-8 (2005). (Pubitemid 41254588)
6. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: A global perspective. Vaccine 17, 1730-1733 (1999). (Pubitemid 29138908)
7. Tozun N, Ozdogan O, Cakaloglu Y et al. A nationwide prevalence study and risk factors for hepatitis A, B, C and D infections in Turkey. Hepatology 52, A789 (2010).
8. Bozdayi AM, Aslan N, Bozdayi G et al. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch. Virol. 149, 2115-2129 (2004). (Pubitemid 39508954)
9. Locasciulli A, Alberti A, Bock R et al. Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe: A survey from the European Bone Marrow Transplant.ation (EBMT) Groupe - Infection Diseases Working Party. Bone Marrow Transplant. 14, 833-837 (1994).
10. Ustun C, Koc H, Karayalcin S et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant. 20, 289-296 (1997). (Pubitemid 27389237)
11. Reed EC, Myerson D, Corey L, Meyers JD. Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. Blood 77, 195-200 (1991).
12. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. European Association for the Study of the Liver. J. Hepatol. 50, 227-242 (2009).
13. Rizzetto M, Cianco A. Chronic HBV-related liver disease. Mol. Aspects Med. 29, 72-84 (2008).
14. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of workshop. Gastroenterology 120, 1828-1853 (2001). (Pubitemid 32523500)
15. Fattovich G, Rugge M, Brollo L et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to antiHBe in chronic hepatitis type B. Hepatology 6, 167-172 (1986). (Pubitemid 16144862)
16. Horowitz MM. Uses and growth of hematopoietic cell transplantation. In:Hematopoietic Cell Transplantation Thomas ED, Blume KG, Forman SJ (Eds). Blackwell, Cambridge, MA, USA, 12 (1999).
17. Thomas ED. Bone marrow transplantation: A review. Semin. Hematol. 36, 95-103 (1999).
18. Arai S, Lee LA, Vogelsang GB. A systematic approach to hepatic complications in hematopoietic stem cell transplantation. J. Hematother. Stem Cell Res. 11, 215-229 (2002). (Pubitemid 34309517)
19. Idilman R, Arat M. Hepatic complications of hematopoietic cell transplantation. Turk. J. Hematol. 25, 111-123 (2008).
20. Hoofnagle JH, Dusheiko GM, Schafer DF et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann. Intern. Med. 96, 447-449 (1982). (Pubitemid 12139868)
21. Liang RHS, Lok ASF, Lai CL, Chan TK, Todd O, Chiu EKW. Hepatitis B infection in patients with lymphomas. Hematol. Oncol. 8, 261-270 (1990).
22. Pinto PC, Hu E, Bernstein-Singer M, Pinter-Brown L, Govindarajan S. Acute hepatic injury after withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 65, 878-884 (1990). (Pubitemid 20063489)
23. Lau GKK, Lee CK, Liang R. Hepatitis B virus infection and bone marrow transplantation. Crit. Rev. Oncol. Hematol. 31, 71-76 (1999). (Pubitemid 29305459)
24. Yeo W, Chan PKS, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J. Med. Virol. 62, 299-307 (2000).
25. Xunrong L, Au WY, Liang R, Lau GKK. Hepatitis B virus reactivation after cytotoxic or immunosuppressive therapy - pathogenesis and management. Rev. Med. Virol. 11, 287-299 (2001). (Pubitemid 33009970)
26. Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin. Liver Dis. 11, 965-991 (2007). (Pubitemid 350019026)
27. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43, 209-220 (2006).
28. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with hematological malignancies. Br. J. Haematol. 136, 699-712 (2007).
29. Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: Guidelines for prevention and management. Intern. Med. J. 37, 705-712 (2007). (Pubitemid 47481164)
30. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 113, 3147-3153 (2009).
31. Rossi G. Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with hemato-oncological neoplasias treated with chemotherapy. Leuk. Lymphoma 44, 759-766 (2003). (Pubitemid 36410979)
32. Idilman R. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. J. Antimicrob. Chemother. 55, 828-831 (2005). (Pubitemid 40883163)
33. Roberts MM, To LB, Gillis D et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant. 12, 469-475 (1993). (Pubitemid 23328360)
34. Talmadge JE, Reed E, Ino K et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant. 19, 161-172 (1997). (Pubitemid 27068253)
35. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 78, 2210-2215 (1996). (Pubitemid 26367616)
36. Yeo W, Chan PKS, Hui P et al. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy: A prospective study. J. Med. Virol. 70, 553-561 (2003). (Pubitemid 36734719)
37. Lau GKK, Leung Y, Fong DYT et al. High hepatitis B virus (HBV) DNA viral load as the most important factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 99, 2324-2330 (2002). (Pubitemid 34525416)
38. Zhong S, Yeo W, Schroder C et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J. Viral Hepatol. 11, 55-59 (2004). (Pubitemid 38221618)
39. Yoshiba M, Sekiyama K, Sugata F, Okamoto H, Yamamoto K, Yotsumoto S. Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment. Dig. Dis. Sci. 37, 1253-1259 (1992).
40. Nagamatsu H, Kumashiro R, Itano S, Matsugaki S, Sata M. Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol. Res. 26, 293-301 (2003). (Pubitemid 37184518)
41. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100, 182-188 (1991).
42. Yeo W, Zhong S, Chan PKS et al. Sequence variation of precore/core and precore promoter regions of hepatitis B virus in patients with or without viral replication during cytotoxic chemotherapy. J. Viral Hepatol. 7, 448-458 (2000).
43. Coiffier B. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatments: Role of lamivudine prophylaxis. Cancer Invest. 24, 548-552 (2006). (Pubitemid 44576409)
44. Evens AM. Jovanovic BD, Su YC et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Meta-analysis and examination of FDA safety reports. Ann. Oncol. DOI: 10.1093/annonc/mdq583 (2010) (Epub ahead of print).
45. Carroll MB. The impact of biologic response modifiers on hepatitis B virus infection. Expert Opin. Biol. Ther. 11, 533-544 (2011).
46. Pei SN, Chen CH, Lee CM et al. Reactivation of hepatitis B virus following rituximab-based regimens: A serious complication in both HBsAg-positive and HBsAg-negative patients. Ann. Hematol. 89, 255-262 (2010).
47. Tsutsumi Y, Ogasawara R, Kamihara Y et al. Rituximab administration and reactivation of HBV. Hepat. Res. Treat. DOI:10.1155/2010/182067 (2010) (Epub ahead of print).
48. Gea-Banacloche JC. Rituximab-associated infections. Semin. Hematol. 187-198 (2010).
49. Aksoy S, Harputluoglu H, Kilickap S et al. Rituximab-related viral infections in lymphoma patients. Leuk. Lymphoma 48, 1307-1312 (2007). (Pubitemid 47079357)
50. Yeo W, Chan TC, Leung NWY et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J. Clin. Oncol. 27, 605-611 (2009).
51. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz A. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc. Natl Acad. Sci. USA 83, 1627-1631 (1986). (Pubitemid 16018617)
52. Tur-Kaspa R, Shaul Y, Moore DD et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 167, 630-633 (1988). (Pubitemid 19037154)
53. Liaw YF. Hepatitis viruses under immunosuppressive agents. J. Gastroenterol. Hepatol. 13, 14-20 (1998).
54. Hsu CH, Hsu HC, Chen HL et al. Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res. 24, 3035-3040 (2004).
55. Yeo W, Lam KC, Zee B et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann. Oncol. 15, 1661-1666 (2004). (Pubitemid 39562607)
56. Degertekin B, Lok AS. Indications for therapy in hepatitis B. Hepatology 49, 129-137 (2009).
57. Wai CT, Lok ASF. Treatment of hepatitis B. J. Gastroenterol. 37, 771-778 (2002). (Pubitemid 35390301)
58. Rossi G, Pelizzari A, Motta M, Puoti M. Primer prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br. J. Haematol. 115, 58-62 (2001). (Pubitemid 32995093)
59. Lim LL, Wai CT, Lee YM et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment. Pharmacol. Ther. 16, 1939-1944 (2002). (Pubitemid 35253010)
60. Lau GKK, He M, Fong DYT et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 36, 702-709 (2002). (Pubitemid 34977182)
61. Lee GW, Ryu MH, Lee JL et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBsAg) positive patients with non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J. Korean Med. Sci. 18, 849-854 (2003).
62. Lau GK, Yiu HH, Fong DY et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125, 1742-1749 (2003). (Pubitemid 37500439)
63. Idilman R, Arat M, Soydan E et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J. Viral Hepatol. 11, 41-47 (2004).
64. Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 24, 540-546 (2004). (Pubitemid 40028604)
65. Sugimoto R, Enjoji M, Kotoh K et al. Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy. Fukuoka Igaku Zasshi 95, 274-279 (2004).
66. Yeo W, Ho WM, Hui P et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res. Treat. 88, 209-215 (2004). (Pubitemid 40137299)
67. Yeo W, Chan PK, Ho WM et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J. Clin. Oncol. 22, 927-934 (2004). (Pubitemid 41103605)
68. Vassiliadis T, Garipidou V, Tziomalos K et al. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematological malignancies treated with chemotherapy - A prospective case series. Am. J. Hematol. 80, 197-203 (2005). (Pubitemid 41579541)
69. Yeo W, Hui EP, Chan AT et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am. J. Clin. Oncol. 28, 379-384 (2005). (Pubitemid 41099543)
70. Hsiao LT, Chiou TF, Liu JH et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplantation. Biol. Blood Marrow Transpl. 12, 84-94 (2006).
71. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: Lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment. Pharmacol. Ther. 24, 1003-1016 (2006). (Pubitemid 44386525)
72. Firpi R, Nelson D. Management of viral hepatitis in hematologic malignancies. Blood Rev. 22, 117-126 (2008).
73. Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation related mortality in chemotherapy patients: A meta-analysis. Liver Int. 28, 28-38 (2008).
74. Loomda R, Rowley A, Wesley R et al. Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann. Intern. Med. 148, 519-528 (2008). (Pubitemid 351665421)
75. Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: A meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Hematologia 94, 998-1005 (2009).
76. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341, 1256-1263 (1999). (Pubitemid 29489740)
77. Lau DT, Khokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32, 828-834 (2000).
78. Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B. antiviral efficacy and viral resistance. Am. J. Gastroenterol. 97, 1618-1628 (2002). (Pubitemid 34761380)
79. Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125, 1714-1722 (2003). (Pubitemid 37500436)
80. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27, 1670-1677 (1998). (Pubitemid 28264693)
81. Zoulim F. Detection of hepatitis B virus resistance to antivirals. J. Clin. Virol. 21, 243-253 (2001). (Pubitemid 32496544)
82. Yuen MF, Sanlon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34, 785-791 (2001). (Pubitemid 32928004)
83. Liaw YF, Chien RN, Yeh CT, Tsai SI, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30, 567-572 (1999).
84. Pelizzari AM, Motta M, Cariani E, Turconi P, Borlenghi E, Rossi G. Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematological malignancies. Hematol. J. 5, 325-328 (2004). (Pubitemid 39214210)
85. Hui CK, Cheung WWW, Au WY et al. Hepatitis B reactivation after withdrawal of preemptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 54, 1597-1603 (2005). (Pubitemid 41531779)
86. Nowak MA, Bonhoeffer S, Hill AM et al. Viral dynamics in hepatitis B virus infection. Proc. Natl Acad. Sci. USA 93, 4398-4402 (1996). (Pubitemid 26144299)
87. Lewin S, Walters T, Locarnini S. Hepatitis B treatment. Rational combination chemotherapy based on viral kinetic and animal model studies. Antiviral Res. 55, 381-396 (2002). (Pubitemid 35223095)
88. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 100, 391-396 (2002). (Pubitemid 34761098)
89. Liu CJ, Lai MY, Lee PH et al. Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: A 4-year experience. J. Gastroenterol. Hepatol. 16, 1001-1008 (2001).
90. Liaw JF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asians patients with chronic hepatitis B. Gastroenterology 119, 172-180 (2000). (Pubitemid 30452590)
91. Idilman R. Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with hemato/oncological malignancies who receive chemotherapy. Gut 55, 1208-1209 (2006). (Pubitemid 44085694)
92. Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: A decision analysis model. Hepatology 46, 1049-1056 (2007). (Pubitemid 350144770)
93. Li YH, He YF, Jiang WQ et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 106, 1320-1325 (2006).
94. Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B virus reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann. Hematol. 83, 270-275 (2004). (Pubitemid 38594322)
95. Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br. J. Haematol. 116, 166-169 (2002).
96. Faggioli P, Paschale MD, Tocci A et al. Acute hepatic toxicity during cyclic chemotherapy in non-Hodgkin's lymphoma. Haematologica 82, 38-42 (1997). (Pubitemid 28023485)
97. Picardi M, Pane F, Quintarelli C et al. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: High prevalence of acquired viral genomic mutations. Haematologica 88, 1296-1303 (2003). (Pubitemid 37456385)
98. Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 46, 2925-2930 (1999). (Pubitemid 29525306)
99. Persico M, De Marino F, Russo GDG et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin's lymphoma. Blood 99, 724-725 (2002). (Pubitemid 34533120)
100. Kumagai K, Takagi T, Sakai C. Prevention of hepatitis development by interferon-alpha in HBV carriers treated with intensive chemotherapy: A pilot study. Ann. Oncol. 9, 117-118 (1998). (Pubitemid 28125775)
101. Picardi M, Selleri C, De Rosa G, Raiola A, Pezzullo L, Rotoli B. Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation. Bone Marrow Transpl. 21, 1267-1269 (1998). (Pubitemid 28318756)
102. Ahmet A, Keeffe EB. Lamivudine therapy in chemotherapy-induced reactivation of hepatitis B virus infection. Am. J. Gastroenterol. 94, 249-251 (1999). (Pubitemid 29063477)
103. Yeo W, Steinberg JL, Tam JS et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J. Med. Virol. 59, 263-269 (1999). (Pubitemid 29468064)
104. Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN. Successful treatment of lamivudine for fulminant hepatitis B infection following intensive therapy for high grade non-Hodgkin's lymphoma. Ann. Oncol. 9, 385-387 (1998). (Pubitemid 28273030)
105. Cainelli F, Longhi MS, Concia E, Vento S. Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B. Am. J. Gastroenterol. 96, 1651-1652 (2001). (Pubitemid 32455116)
106. Petrelli E, Balducci M, Pieretti C, Rocchi MB, Clementi M, Manzin A. Lamivudine treatment failure in preventing fatal outcome of the de novo severe acute hepatitis B in patients with hematological diseases. J. Hepatol. 35, 823-826 (2001). (Pubitemid 34717677)
107. Strasser SI, McDonald GB. Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management. Blood 93, 1127-1136 (1999). (Pubitemid 29076126)
108. Locasciulli A, Alberti A, Bandini G et al. Allogeneic bone marrow transplantation from HBsAg-positive donors: A multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 86, 3236-3240 (1995).
109. Lau GKK, Lie AKW, Kwong YK et al. A-case controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation. Blood 96, 452-458 (2000). (Pubitemid 30463362)
110. Arnold DM, Crowther MA, Meyer RM et al. Misleading hepatitis B test results due to intravenous immunoglobulin administration: Implications for a clinical trial of rituximab in immune thrombocytopenia. Transfusion 50, 2577-2581 (2010).
111. Brost S, Schnitzler P, Stremmel W, Eisenbach C. Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. World J. Gastroenterol. 16, 5447-5451 (2010).
112. Idilman R, Ustun C, Karayalcin S et al. Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation. Clin. Transplant. 17, 438-443 (2003). (Pubitemid 37236117)
113. Mason AL, Xu LZ, Guo LS, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 27, 1736-1742 (1998). (Pubitemid 28264703)
114. Ljungman P, Engelhard D, de la Camara R et al. Vaccination of stem cell transplant recipients: Recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transpl. 35, 737-746 (2005). (Pubitemid 40613780)
115. Hui CK, Lie A, Au WY et al. Effectiveness of prophylactic anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. Am. J. Transpl. 5, 1437-1445 (2005). (Pubitemid 40839436)
116. Idilman R, Colantoni A, De Maria N et al. Impaired antibody response rates after high dose short interval hepatitis B virus vaccination of immunosuppressed individuals. Hepatogastroenterology 50, 217-221 (2003). (Pubitemid 36182971)
117. Peggs KS. Reconstitution of adaptive and innate immunity following allogeneic hematopoietic stem cell transplantation in humans. Cytotherapy 8, 427-436 (2006). (Pubitemid 44596995)
118. Strasser SI, McDonald GB. Gastrointestinal and hepatic complications. In:Thomas's Hematopoietic Cell Transplantation Blume K, Forman SJ, Appelbaum FR (Eds). Blackwell, Queensland, Australia, 769-810 (2004).
119. McCrudden R, Williams DB, O'Connor T, Vickers CR. Gastrointestinal, hepatic, gallbladder, pancreatic, and perianal complications. In:Clinical Bone Marrow and Stem Cell Transplantation Atkinson K, Champlin R, Ritz J, Fibbe WE, Brenner MK (Eds). Cambridge University Press, Cambridge, UK, 1417-1453 (2004).
120. Locasciulli A, Testa M, Valsecchi MG et al. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: A prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation 68, 1486-1491 (1999).
121. Lindemann M, Barsegian V, Runde V et al. Transfer of humoral and cellular hepatitis B immunity by allogeneic hematopoietic cell transplantation. Transplantation 75, 833-838 (2003). (Pubitemid 36373457)
122. Shouval D, Ilan Y. Immunization against hepatitis B through adoptive transfer immunity. Intervirology 38, 41-46 (1995).
123. Ilan Y, Nagler A, Adler R et al. Adoptive immunity transfer of immunity to hepatitis B virus after T-cell depleted allogeneic BMT. Hepatology 18, 246-252 (1993). (Pubitemid 23225091)
124. Shouval D, Adler R, Ilan Y. Adoptive transfer of immunity to hepatitis B virus in mice by BMT from immune donors. Hepatology 17, 955-959 (1993). (Pubitemid 23187395)
125. Lau GKK, Lok ASF, Liang RHS et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: Role of adoptive immunity transfer. Hepatology 25, 1497-1501 (1997). (Pubitemid 27250775)
126. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N. Engl. J. Med. 336, 196-204 (1997). (Pubitemid 27034966)
127. Van Thiel DH. Vaccination of patients with liver disease: Who, when, and how. Liver Transpl. Surg. 4, 185-187 (1998).
128. Peces R, de la Torre M, Alcazar R, Urra JM. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am. J. Kidney Dis. 29, 239-245 (1997). (Pubitemid 27130735)
129. Hadler SC, Margolis HS. Hepatitis B immunization: Vaccine types, efficacy, and indications for immunization. In:Current Clinical Topics in Infectious Diseases Remington JS, Swartz MN (Eds). Blackwell Scientific, Boston, MA, USA, 282-308 (1992).
130. Rahman F, Dahren A, Herzog-Hauff S, Bocher WO, Galle PR, Lohr HF. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 31, 521-527 (2000). (Pubitemid 30078622)
131. De Maria N, Idilman R, Colantoni A, Harig J, Van Thiel DH. Antibody response to HBV vaccination in individuals with HCV infection. Hepatology 32, 444-445 (2000).
132. Egea E, Iglesias A, Salazar M et al. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J. Exp. Med. 173, 531-538 (1991).
133. Nagler A, Ilan Y, Adler R et al. Successful immunization of autologous bone marrow transplantation recipients against hepatitis B virus by active vaccination. Bone Marrow Transplant. 15, 475-478 (1995).
134. Wimperis JZ, Brenner MK, Prentice HG et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1, 339-343 (1986). (Pubitemid 16137799)
135. Lau GKK, Liang R, Lee CK et al. Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- And anti-hepatitis B surface antibody-positive. J. Infect. Dis. 178, 1585-1591 (1998). (Pubitemid 28558127)
136. Picardi M, DeRosa G, Selleri C, Pane F, Rotoli B, Muretto P. Clinical revelance of intrahepatic hepatitis B virus DNA in HBsAg-negative HBcAb-positive patients undergoing hematopoietic stem cell transplantation for hematological malignancies. Transplantation 82, 141-142 (2006). (Pubitemid 44296993)
137. Mulrooney-Cousins PM, Michalak TI. Persistent occult hepatitis B virus infection: Experimenthal findings and clinical implications. World J. Gastroenterol. 13, 5682-5686 (2007). (Pubitemid 350120219)
138. Ciesek S, Helfritz FA, Lehman U et al. Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver. J. Infect. Dis. 197, 355-360 (2008). (Pubitemid 351263416)
139. Goyama S, Kanda Y, Nannya Y et al. Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation. Leuk. Lymphoma 43, 2159-2163 (2002). (Pubitemid 35174730)
140. Knoll A, Boehm S, Hahn J, Holler E, Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 33, 925-929 (2004). (Pubitemid 38660126)
141. Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant 15, 1049-1059 (2009).
142. Vigano M, Vener C, Lampertico P et al. Risk of hepatitis B surface antigen seroconversion after allogeneic hematopoietic SCT. Bone Marrow Transplant. 46, 125-131 (2011).